Articles related to VACCINES/IMMUNIZATION

The 100-μg dose of the ERBB2 ICD plasmid-based vaccine was associated with the generation of ERBB2-specific type 1 T cells in the majority of patients with ERBB2-expressing breast cancer in this phase 1 nonrandomized clinical trial, and it is currently being assessed in randomized phase 2 trials.

In a cohort study of more than 2 million patients, influenza vaccination was associated with a 22% to 24% lower risk of SARS-CoV-2 infection. But more than half of that effect seems to be that healthier people are more likely to be vaccinated for flu.

This case-control study carried out at six hospitals between Oct 2021 and July 2022 found that boosters yielded a 75% reduction in COVID hospitalization risk in the first 50 days post-booster, declining to 25% reduction in hospitalization risk at over 150 days. Other factors associated with an increased odds of hospitalization for COVID-19 included age of 70 years or older, male sex, cognitive disease, COPD, diabetes, immunodeficiency, obesity, rheumatologic disease, transplant, and Pfizer-BioNTech vaccination.

In this cross-sectional study of US adults hospitalized with COVID-19 during January 2022 to April 2022, hospitalization rates from COVID were 10.5 times higher in unvaccinated persons and 2.5 times higher in vaccinated persons with no booster dose, respectively, compared with those who had received a booster dose.

All vaccines are expected to be quadrivalent. Included in the update are expanded approval for Flucelvax Quadrivalent, administration adjustments for Afluria Quadrivalent, and higher dose vaccines for those 65 years old and older.

To assess short-term risk for severe cardiovascular events (excluding myocarditis and pericarditis) after COVID-19 vaccination, adults younger than 75 years hospitalized for PE, acute MI, hemorrhagic stroke, or ischemic stroke (73,325 events) were reviewed in relation to a 1st or 2nd COVID vaccine dose. No association was found between the Pfizer–BioNTech or Moderna vaccine and severe cardiovascular events. The first dose of the Oxford–AstraZeneca vaccine was associated with acute MI and PE in the second week after vaccination. An association with MI in the second week after a single dose of the Janssen vaccine could not be ruled out.